744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3)

• Aranzazu Manzano,
• Emiliano Calvo,
• Sarina A Piha-Paul,
• Yangchun Du,
• Nehal J Lakhani,
• Rita Dalal,
• Alexander I Spira,
• Sonali Panchabhai,
• Justin A Call,
• Maria J de Miguel,
• Shwetha Asha,
• Clifford DiLea,
• Bhaskar Rege

Affiliations

Aranzazu Manzano

1Department of Medical Oncology, Hospital Clínico San CArlos, Madrid, Spain

Emiliano Calvo

4START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

Sarina A Piha-Paul

1Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Yangchun Du

1Alkermes, Inc., Waltham, MA, USA

Nehal J Lakhani

START Midwest, Grand Rapids, Michigan, USA

Rita Dalal

9Alkermes, Inc, Waltham, MA

Alexander I Spira

2Virginia Cancer Specialists, Fairfax, VA, USA

Sonali Panchabhai

1Alkermes, Inc., Waltham, MA, USA

Justin A Call

20START Mountain Region, West Valley City, UT, USA

Maria J de Miguel

5START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

Shwetha Asha

6Alkermes, Inc., Waltham, MA, USA

Clifford DiLea

6Alkermes, Inc., Waltham, MA, USA

Bhaskar Rege

6Alkermes, Inc., Waltham, MA, USA